258
Participants
Start Date
November 10, 2021
Primary Completion Date
July 26, 2023
Study Completion Date
July 26, 2023
Revefenacin 175 mcg in 3 ML Inhalation Solution
Revefenacin
Placebo inhalation solution QD
Placebo
Inner Mongolia People's Hospital, Hohhot
Affiliated Hospital of Inner Mongolia Medical College, Hohhot
Peking University Third Hospital, Beijing
Beijing Hospital, Beijing
The First Hospital of China Medical University, Shenyang
Shengjing Hospital of China Medical University, Shenyang
The First Bethune Hospital of Jilin University, Changchun
Yanbian university hospital, Yanji
Shanghai East Hospital, Shanghai
Shanghai Pudong New Area People's Hospital, Shanghai
Zhongda Hospital, Southeast University - Pulmonology, Nanjing
Nanjing Jiangning Hospital, Nanjing
Wuxi People's Hospital, Wuxi
Jiangsu Jiangyin People's Hospital, Jiangyin
Yangzhou First People's Hospital, Yangzhou
Anhui Medical University - Hefei First People's Hospital, Hefei
Tianjin Medical University General Hospital - Respiration, Tianjin
The First Center hospital of Tianjin, Tianjin
Xinhua Hostipal of Zhejiang Province, Hangzhou
Huzhou Central Hospital, Huzhou
Dongyang People's Hospital, Dongyang
Jiangxi Provincial People's Hospital, Nanchang
Nanchang University - The Second Affiliated Hospital, Nanchang
Sichuan University - West China Hospital, Chengdu
Jiangxi Pingxiang People's Hospital, Pingxiang
The First Hospital of Changsha, Changsha
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou
The Third Affiliated Hospital Of Guangzhou Medical University, Guangzhou
Guangzhou First People's Hospital, Guangzhou
The Second Affiliated Hospital Of Guangzhou Medical University, Guangzhou
Affiliated Hospital of Guangdong Medical University, Guangzhou
Hainan General Hospital, Haikou
The First Affiliated Hospital of Xinjiang Medical University - Hospital, Ürümqi
Inner Mongolia Baogang Hospital, Baotou
The First Affiliated Hospital of Baotou Medical College - Respiration, Baotou
Mylan Pharma UK Ltd.
INDUSTRY